Can RNA editing take Atlas startup where Vertex couldn't go? Korro lands $116M to find out
As the CEO of RNA editing startup Korro Bio, Ram Aiyar often gets the same question.
“I get always asked, you know, if you can fix DNA, why bother with RNA?” he told Endpoints News. “And it’s like asking, which child do you prefer — your older one or your younger one?”
But investors are appreciating the difference. More than a year after closing its Series A just shy of the megaround mark, Korro Bio is back in the spotlight with $116 million in fresh cash and a lead candidate — targeting alpha-1 antitrypsin deficiency, or AATD.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.